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Objective
• QSAR and molecular docking studies for immunomodulatory activity of 
gallic acid & its derivative
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QSAR and molecular docking studies for immunomodulatory activity of gallic 
acid & its derivative
 Literature survey and retrieval of known drugs/compounds
 Prepared a library for immunomodulatory activity 
 Minimized  all  the molecules and calculate the descriptors  for 
regression analyses
 Developed  the mathematical multiple linear regression QSAR 











































































Predicted activity by the constructed model are in good with the experimental data, suggesting that these model should have a
satisfactory predictive ability
QSAR studies 
Predicted log LD50 (mg/kg) = -0.156436 * Dipole Moment (debye) 
-0.00118794 * Steric Energy (kcal/mole) 
+0.910351 * Amide group count 
+0.0206362 * λ max (UV-visible) (nm) 



































































































































































G-1 G-2 G-3 G-4
G-5 G-6 G-7 G-8
G-9 G-10 G-11
G-12 G-13











































































































































G-7 (Pred. LD50= 190.99 mg/kg) G-4 (Pred. LD50= 212.81 mg/kg)
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SloveniaCompound G-4 docked on  INFα-2 with docking energy -59.87 kcal/mol and H-bond of 2.045 Å to binding pocket residue LYS-15
Compound G-10 docked on  INFα-2 
with docking energy -70.26 kcal/mol 
and H-bond of 2.029 Å to binding 
pocket residue GLU-108
Compound G-7 docked on 
INFα-2 with docking energy -
60.59 kcal/mol and H-bond of 
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Compound G-7 docked on IL-4 with docking energy -87.55 kcal/mol 
and H-bond of 2.85 Å to binding pocket residue ARG-175
Compound G-5 docked on  IL-4 with docking energy -86.25 kcal/mol 
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Binding affinity of gallic acid derivative with IL 6 receptor
Compound G-10 docked on IL-6 with docking energy -94.44 kcal/mol 
and H-bond of 2.115 Å to binding pocket residue LYS-105
Compound G-5 docked on r IL-6 with docking energy -87.73 
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Drug likeness properties of gallic acid derivative
Compound Pharmacokinetic property (ADME) dependent on chemical descriptors Rule of 5























Levamisol 40.9 204.29 3.259 0 0 0 2 0 0
G-1 64.99 338.35 3.228 0 0 1 0 5 0
G-2 53.99 450.48 3.832 0 0 0 0 7 0
G-3 91.29 424.44 3.243 0 0 2 0 7 0
G-4# 80.29 424.44 3.175 0 0 0 0 7 0
G-5 91.29 396.39 2.801 0 0 0 0 7 0
G-6 80.29 438.47 3.357 0 0 0 0 7 0
G-7# 97.36 452.46 2.712 0 0 0 0 8 0
G-8 80.29 460.43 4.377 0 0 0 0 7 0
G-9# 97.08 421.44 2.593 0 0 0 1 6 0
G-10# 83.09 497.54 5.23 0 1 0 1 6 1
G-12# 83.09 477.55 4.047 0 1 0 1 6 0
G-13# 110.78 587.62 3.763 0 1 0 1 9 1
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Principal Descriptors:                             Levamisol G-3 G-4# G-5 G-6 G-7# G-10# Stand. Range*
log S  for   aqueous solubility -3.476 -5.549 -5.378 -4.425 -5.598 -5.297 -7.594 (-6.5 / 0.5) 
log Khsa Serum Protein Binding 0.112 0.266 0.319 -0.004 0.394 -0.020 0.964 (-1.5 / 1.5) 
log BB for brain/blood 0.462 -1.546 -0.924 -1.240 -0.923 -1.526 -1.023 (-3.0 / 1.2) 
No. of metabolic reactions 2 5 5 5 5 5 6 (1.0 / 8.0) 
Predicted CNS Activity   +2 -2 -1 -2 -1 -2 -2 –2 (inactive),
+2 (active)
Log IC50 for HERG K+ Channel 
Blockage
-4.198 -4.306 -6.116 -3.717 -6.193 -6.721 -7.702 (concern below -5)
Apparent Caco-2 Permeability (nm/sec)  5589 99 1448 131 1682 597 1580 (<25 poor, >500 
great)
Apparent MDCK   Permeability (nm/sec)    5839 51 738 70 867M 283M 811M (<25 poor, >500 
great)
log Kp for skin permeability -3.392 -2.469 -1.425 -2.377 -1.210 -1.971 -0.482 (–8.0 to –1.0, Kp in 
cm/hr)
Jm, max transdermal transport rate 0.028 0.004 0.067 0.063 0.068 0.024 0.004 (micrograms/cm^2-
hr)
Jorgensen Rule of 3 Violations     0 0 0 0 0 0 1 (maximum is 3)
% Human Oral Absorption in GI (+-20%)   100 89 100 87 100 100 89 (<25% is poor)
Qual. Model for Human Oral Absorption HIGH HIGH HIGH HIGH HIGH HIGH Low (>80% is high)
Computational parameters of pharmacokinetics (ADME) studies 
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Compliance of active gallic acid derivatives to computational 
toxicity risks parameters
Compound Toxicity risk parameters Drug likeness parameters (Osiris)
MUT TUMO IRRI REP MW CLP S DL DS
Levamisol  No risk No risk No risk No risk 206 1.38     -1.52 3.73       0.95    
G-3 Medium 
risk
No risk High risk No risk 422 3.67 -5.48 4.81 0.25
G-4# Medium 
risk
No risk No risk No risk 424 3.99 -5.6 0.24 0.31
G-5 Medium 
risk
No risk No risk No risk 396 3.1 -5.17 4.21 0.48
G-6 Medium 
risk
No risk Medium 
risk
No risk 438 4.45 -5.87 -6.57 0.14
G-7# Medium 
risk
No risk No risk No risk 452 3.35 -5.52 -10.7 0.21
G-9# Medium 
risk
No risk High risk No risk 421 3.13 -5.56 3.35 0.26
G-10# Medium 
risk
No risk High risk No risk 497 5.23 -6.98 2.55 0.14
G-12# Medium 
risk
No risk High risk No risk 477 5.01 -6.31 2.42 0.16
G-13# Medium 
risk
No risk High risk No risk 587 4.92 -7.03 4.23 0.13
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QSAR model for cytotoxic activity against lungs cancer cell line (A-549)
 Prepared a library for lung cancer cell line (A-549)
 Minimized  all  the molecules and calculate the descriptors  for 
regression analyses
 Developed  the mathematical multiple linear regression QSAR 












































































Predicted log IC50 (microM) = =-0.125338* Dipole Moment (debye) 
-0.00353339* Steric Energy (kcal/mole) 
-0.405538* HOMO Energy (eV) 
+0.459862* LUMO Energy (eV) 
-0.00475691* Solvent Accessibility Surface Area (Â) 





































































































G-10 (Pred. IC50= 0.71 µM) G-11 (Pred. IC50= 0.77 µM)


























O Paclitaxel (Exp. IC50= -1.824 µM
(control)
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• Binding site residues of INFα-2 indicate H-bond formation with    compounds 
G-4, G-7 and G-10
• Compounds G-5 and G-10 form the H-bond with IL-6 binding site residues
• Binding site residues of IL-4 indicate H-bond formation with compounds G-5,   
and G-7, thus considered more stable and potent.
• Results of anticancer QSAR showed that compounds G-10, G-11 and G-13 
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Multiple linear regression analysis of anti-inflamtary activity
Predicted logLD50 (mg/kg) = +0.207651 x Dipole Vector X (debye) (L)
-0.0872917 x Dipole Vector Y (debye) (M)
+0.0150386 x Steric Energy (kcal/mole) (Q)
+0.102653 x LUMO Energy (eV) (Z)
+1.26128 x Size of Smallest Ring (AE)
+0.563956 x Size of Largest Ring (AF)
-0.724896 x Group Count (carboxyl) (AM)
-7.41586
[rCV2=0.867314 and r2=0.918119]
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Molecular structure of the natural coumarinolignoids showing fusion of coumarin moiety with 
the phenylpropanoid unit (lignan) and superimposition of most favourable conformations of 
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Binding affinity of Cleomiscosin A, B and C with various immune 
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Molecular docking based identification of potential immuno-
modulatory targets of cleomiscosin molecules
Coumarinolignoids Potential Target
Cleomiscosin A (1a) TLR-4 
Cleomiscosin B (2a) iNOS, COX-2, CD14, IKK ß
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Thanks for your attention !!
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